{'fraction_non_alphanumeric': 0.06026058631921824, 'fraction_numerical': 0.07573289902280131, 'mean_word_length': 5.0245098039215685, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
SLC2A3 rs12842 polymorphism and risk for Alzheimer’s disease

ABSTRACT Background Many studies support the hypothesis that brain glucose dysregulation contributes to neurodegeneration and disease progression. The SLC2A3 gene encodes the Neuronal Glucose Transporter 3 (GLUT3), a critical molecule for glucose transport into the neuron. The GLUT3 rs12842 polymorphism has been associated with an increased risk for attention-deficit/hyperactivity disorder (ADHD). Epidemiological and genetic studies have reported a link between antecedent ADHD and Alzheimer’s disease (AD), as both share a dysregulation of brain glucose. Aim This study aimed to explore the possible correlation of the SLC2A3 rs12842 polymorphism with susceptibility towards AD. Methods We genotyped 327 patients with AD and 327 controls for the GLUT3 rs12842. Results: Rs12842 was associated with a decreased risk of developing AD in the co-dominant [Odds Ratio (OR) (95% confidence interval (CI) = 0.67 (0.45–0.99)), p = 0.039], dominant [OR (95% CI) = 0.64 (0.44–0.93), p = 0.019] and log-additive modes [OR (95% CI) = 0.65 (0.46–0.91), p = 0.012]. Conclusions Our results suggest a significant, inverse association between SLC2A3 rs12842 and the risk of AD.